Results 1 to 10 of about 74,186 (118)
Flagellin as a vaccine adjuvant
Expert Review of Vaccines, 2018 Bacterial flagellin, as a pathogen-associated molecular pattern (PAMP), can activate both innate and adaptive immunity. Its unique structural characteristics endow an effective and flexible adjuvant activity, which allow the design of different types of vaccine strategies to prevent various diseases.
Xinsheng Liu +2 more
exaly +4 more sources
Adjuvants for human vaccines [PDF]
Current Opinion in Immunology, 2012 Rational selection of individual adjuvants can often be made on the basis of innate molecular interactions of the foreign molecules with pattern recognition receptors such as Toll-like receptors. For example, monophosphoryl lipid A, a family of endotoxic TLR4 agonist molecules from bacteria, has recently been formulated with liposomes, oil emulsions ...
Carl R, Alving +3 more
openaire +2 more sources
Adjuvanted influenza vaccines [PDF]
Human Vaccines & Immunotherapeutics, 2018 In spite of current influenza vaccines being immunogenic, evolution of the influenza virus can reduce efficacy and so influenza remains a major threat to public health. One approach to improve influenza vaccines is to include adjuvants; substances that boost the immune response.
John S. Tregoning +2 more
openaire +4 more sources
Adjuvants for Coronavirus Vaccines [PDF]
Frontiers in Immunology, 2020 Vaccine development utilizing various platforms is one of the strategies that has been proposed to address the coronavirus disease 2019 (COVID-19) pandemic. Adjuvants are critical components of both subunit and certain inactivated vaccines because they induce specific immune responses that are more robust and long-lasting.
Zhihui Liang +15 more
openaire +3 more sources
Adjuvanted influenza vaccines [PDF]
Human Vaccines & Immunotherapeutics, 2012 The search for adjuvants has been stimulated by the need to ensure greater protection against influenza among subjects who show a reduced immune response to conventional influenza vaccines. Aluminum salts have long been used but are not considered satisfactory.
N. Principi, S. Esposito
openaire +5 more sources
Adjuvants for allergy vaccines [PDF]
Human Vaccines & Immunotherapeutics, 2012 Allergen-specific immunotherapy is currently performed via either the subcutaneous or sublingual routes as a treatment for type I (IgE dependent) allergies. Aluminum hydroxide or calcium phosphate are broadly used as adjuvants for subcutaneous allergy vaccines, whereas commercial sublingual vaccines rely upon high doses of aqueous allergen extracts in ...
openaire +2 more sources
Advances in vaccine adjuvants [PDF]
Nature Biotechnology, 1999 Currently, aluminum salts and MF59 are the only vaccine adjuvants approved for human use. With the development of new-generation vaccines (including recombinant subunit and mucosal vaccines) that are less immunogenic, the search for more potent vaccine adjuvants has intensified.
M, Singh, D, O'Hagan
openaire +2 more sources
Expert Review of Vaccines, 2011 Adjuvants are essential components of most clinically used vaccines. This is because the majority of nonliving vaccines are relatively poor inducers of adaptive immunity unless effective adjuvants are co-administered. Aluminum salts (alum) have been used as adjuvants with great success for almost a century and have been particularly effective at ...
Schijns, V.E.J.C., Lavelle, E.C.
openaire +2 more sources
Vaccines, adjuvants and autoimmunity
Pharmacological Research, 2015 Vaccines and autoimmunity are linked fields. Vaccine efficacy is based on whether host immune response against an antigen can elicit a memory T-cell response over time. Although the described side effects thus far have been mostly transient and acute, vaccines are able to elicit the immune system towards an autoimmune reaction.
Luísa Eça Guimarães +3 more
openaire +2 more sources
Chemokines as Cancer Vaccine Adjuvants [PDF]
Vaccines, 2013 We are witnessing a new era of immune-mediated cancer therapies and vaccine development. As the field of cancer vaccines advances into clinical trials, overcoming low immunogenicity is a limiting step in achieving full success of this therapeutic approach.
Bobanga, Iuliana D +2 more
openaire +4 more sources